74 related articles for article (PubMed ID: 19887873)
1. Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases.
Levchenko EV; Moiseyenko VM; Matsko DE; Iyevleva AG; Ivantsov AO; Yargnian SM; Anisimov VV; Semionov II; Imyanitov EN
Onkologie; 2009 Nov; 32(11):674-7. PubMed ID: 19887873
[TBL] [Abstract][Full Text] [Related]
2. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
3. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
4. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
5. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
6. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
10. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC
Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.
Miyanaga A; Gemma A; Ando M; Kosaihira S; Noro R; Minegishi Y; Kataoka K; Nara M; Okano T; Miyazawa H; Tanaka T; Yoshimura A; Kobayashi K; Iwanami H; Hagiwara K; Tsuboi E; Kudoh S
Oncol Rep; 2008 Feb; 19(2):377-83. PubMed ID: 18202784
[TBL] [Abstract][Full Text] [Related]
12. Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
Yamamoto Y; Kodama K; Maniwa T; Takeda M
J Cardiothorac Surg; 2017 Nov; 12(1):98. PubMed ID: 29169381
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB
J Clin Oncol; 2009 Dec; 27(36):6229-36. PubMed ID: 19884551
[TBL] [Abstract][Full Text] [Related]
14. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Chang CC; Chi KH; Kao SJ; Hsu PS; Tsang YW; Chang HJ; Yeh YW; Hsieh YS; Jiang JS
Lung Cancer; 2011 Aug; 73(2):189-94. PubMed ID: 21247653
[TBL] [Abstract][Full Text] [Related]
15. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
Ushiki A; Koizumi T; Kobayashi N; Kanda S; Yasuo M; Yamamoto H; Kubo K; Aoyagi D; Nakayama J
Jpn J Clin Oncol; 2009 Apr; 39(4):267-70. PubMed ID: 19155283
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
17. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
[TBL] [Abstract][Full Text] [Related]
18. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Wu JY; Wu SG; Yang CH; Chang YL; Chang YC; Hsu YC; Shih JY; Yang PC
Lung Cancer; 2011 May; 72(2):205-12. PubMed ID: 20832137
[TBL] [Abstract][Full Text] [Related]
19. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
20. First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
Lange T; Müller-Tidow C; Serve H; Hoffknecht P; Berdel WE; Thomas M
Oncol Rep; 2005 Dec; 14(6):1539-42. PubMed ID: 16273252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
